Management of difficult-to-treat patients with ulcerative colitis: Focus on adalimumab

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 289-296

  Armuzzi, Alessandro ^a   Pugliese, Daniela ^a   Nardone, Olga Maria ^a   Guidi, Luisa ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Randomized controlled trials; Real life experiences

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; HYDROCORTISONE; INFLIXIMAB; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

CLINICAL PRACTICE; DISEASE ACTIVITY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; INJECTION SITE REACTION; LOADING DRUG DOSE; PATIENT CARE; PSORIASIS; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT DURATION; TREATMENT INDICATION; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; COLITIS, ULCERATIVE;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; COLITIS, ULCERATIVE; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84876021886     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S33197     Document Type: Review

References (37)

1. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6(10):965-990.
2. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19 Suppl A:5-36.
3. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323(18):1228-1233.
4. Solberg IC, Lygren I, Jahnsen J, et al; IBSEN Study Group. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44(4):431-440.
5. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132(2):763-786.
6. Ford AC, Achkar JP, Khan KJ, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):601-616.
7. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6(10):991-1030.
8. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462-2476.
9. Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55(1):47-53.
10. Panaccione R, Rutgeerts P, Sandborn WJ, Feagan B, Schreiber S, Ghosh S. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28(6):674-688.
11. Armuzzi A, Pugliese D, Danese S, et al. Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. Inflamm Bowel Dis. Epub February 27, 2013.
12. Laharie D, Bourreille A, Branche J, et al; Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012;380(9857):1909-1915.
13. Moskovitz DN, Van Assche G, Maenhout B, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol. 2006;4(6):760-765.
14. HUMIRA® (adalimumab) subcutaneous injection [product monograph]. North Chicago, IL: Abbott Laboratories, Ltd; 2012.
15. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323-333.
16. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132(1):52-65.
17. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146(12):829-838.
18. Panaccione R, Colombel JF, Sandborn WJ, et al. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. Aliment Pharmacol Ther. 2010;31(12):1296-1309.
19. Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut. 2009;58(7):940-948.
20. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60(6):780-787.
21. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(2):257-265.
22. Reinisch W, Sandborn WJ, Kumar A, Pollack PF, Lazar A, Thakkar RB. 52-week clinical efficacy with adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppresants. Gut. 2011;60 Suppl 1:A139-A140.
23. Sandborn WJ, Colombel JF, D'Haens G, et al. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther. 2013;37(2):204-213.
24. Feagan BG, Sandborn WJ, Thakkar RB, et al. Adalimumab induction dose reduces the risk of hospitalizations and colectomies in patients with ulcerative colitis during the first 8 weeks of therapy. Gut. 2012;61 Suppl 3:A283.
25. Feagan BG, Sandborn WJ, Skup M, et al. Adalimumab therapy reduces hospitalization and colectomy rates in patients with ulcerative colitis among initial responders. Gut. 2012;61 Suppl 3:A164.
26. Colombel JF, Sandborn WJ, Wolf D, et al. Long term efficacy of adalimumab for treatment of moderate to severe ulcerative colitis. Gut. 2012;61 Suppl 3:A80.
27. Oussalah A, Laclotte C, Chevaux JB, et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther. 2008;28(8):966-972.
28. Afif W, Leighton JA, Hanauer SB, et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009;15(9):1302-1307.
29. Hudis N, Rajca B, Polyak S, Zeilman CJ, Valentine JF. The outcome of active ulcerative colitis treated with adalimumab. Gastroenterology. 2009;136(5 Suppl 1):A661.
30. Gies N, Kroeker KI, Wong K, Fedorak RN. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. Aliment Pharmacol Ther. 2010;32(4):522-528.
31. Taxonera C, Estellés J, Fernández-Blanco I, et al. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther. 2011;33(3):340-348.
32. McDermott E, Murphy S, Keegan D, O'Donoghue D, Mulcahy H, Doherty G. Efficacy of adalimumab as a long term maintenance therapy in ulcerative colitis. J Crohns Colitis. 2013;7(2):150-153.
33. Ferrante M, Karmiris K, Compernolle G, et al. Efficacy of adalimumab in patients with ulcerative colitis: restoration of serum levels after dose escalation results in a better long-term outcome. Gut. 2011;60 Suppl 3:A72.
34. García-Bosch O, Gisbert JP, Cañas-Ventura A, et al. Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. J Crohns Colitis. 2012. Epub November 8, 2012.
35. Armuzzi A, Biancone L, Daperno M, et al. Adalimumab in active ulcerative colitis: a "real-life" observational study. Dig Liver Dis. In press 2013.
36. Burmester GR, Mease P, Dijkmans BA, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis. 2009;68(12):1863-1869.
37. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology. 2009;137(5):1628-1640.